Skip to main content

Research Repository

Advanced Search

All Outputs (181)

Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans (2021)
Journal Article
Llewellyn, H. P., Vaidya, V. S., Wang, Z., Peng, Q., Hyde, C., Potter, D., Wang, J., Zong, Q., Arat, S., Martin, M., Masek-Hammerman, K., Warner, R., Johnson, K., Kullak-Ublick, G. A., Aithal, G. P., Dear, J. W., & Ramaiah, S. K. (2021). Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans. Toxicological Sciences, 181(1), 23-34. https://doi.org/10.1093/toxsci/kfab003

Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and post marketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury - glutamate... Read More about Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans.

Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home (2021)
Journal Article
Tsien, C., Tan, H., Sharma, S., Palaniyappan, N., Wijayasiri, P., Leung, K., Hayre, J., Mowlem, E., Kang, R., Eddowes, P. J., Wilkes, E., Venkatachalapathy, S. V., Guha, I. N., Antonova, L., Cheung, A. C., Griffiths, W. J., Butler, A. J., Ryder, S. D., James, M. W., Aithal, G. P., & Aravinthan, A. D. (2021). Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home. Clinical Medicine, 21(1), e32-e38. https://doi.org/10.7861/clinmed.2020-0609

Introduction: Increasing rates of liver transplantation and improved outcomes have led to greater numbers of transplant recipients followed up in non-transplant centres. Our aim was to document long-term clinical outcomes of liver transplant recipien... Read More about Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home.

MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability (2020)
Journal Article
Scott, R. A., Williams, H. G., Hoad, C. L., Alyami, A., Ortori, C. A., Grove, J. I., Marciani, L., Moran, G. W., Spiller, R. C., Menys, A., Aithal, G. P., & Gowland, P. A. (2021). MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability. Journal of Magnetic Resonance Imaging, 53(5), 1422-1431. https://doi.org/10.1002/jmri.27463

Background: Increased small bowel permeability leads to bacterial translocation, associated with significant morbidity and mortality. Biomarkers are needed to evaluate these changes in vivo, stratify an individual's risk, and evaluate the efficacy of... Read More about MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability.

Non-alcoholic fatty liver disease: Not time for an obituary just yet! (2020)
Journal Article
Singh, S. P., Anirvan, P., Reddy, K. R., Conjeevaram, H. S., Marchesini, G., Rinella, M. E., Madan, K., Petroni, M. L., Al-Mahtab, M., Caldwell, S. H., Aithal, G. P., Hamid, S. S., Farrell, G. C., Satapathy, S. K., Duseja, A., Acharya, S. K., Dassanayake, A. S., & Goh, K.-L. (2021). Non-alcoholic fatty liver disease: Not time for an obituary just yet!. Journal of Hepatology, 74(4), 972-974. https://doi.org/10.1016/j.jhep.2020.10.015

Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens (2020)
Journal Article
Nicoletti, P., Devarbhavi, H., Goel, A., Venkatesan, R., Eapen, C. E., Grove, J. I., Zafer, S., Bjornsson, E., Lucena, M. I., Andrade, R. J., Pirmohamed, M., Wadelius, M., Larrey, D., Maitland-van der Zee, A.-H., Ibanez, L., Watkins, P. B., Daly, A. K., & Aithal, G. P. (2021). Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 109(4), 1125-1135. https://doi.org/10.1002/cpt.2100

Drug‐induced liver injury (DILI) is a complication of treatment with anti‐tuberculosis (TB) drugs, especially in isoniazid‐containing regimens. To investigate genetic risk factors, we performed a genome‐wide association study (GWAS) involving anti‐TB... Read More about Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens.

Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation (2020)
Journal Article
Knight, H., Harman, D., Morling, J. R., Aithal, G., Card, T., Guha, I. N., & Bains, M. (2020). Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation. BMJ Open, 10(11), Article e041574. https://doi.org/10.1136/bmjopen-2020-041574

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. OBJECTIVES: The increasing incidence of chronic liver disease (CLD) in the UK may be attributed to a rise in... Read More about Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation.

Guidelines on the management of ascites in cirrhosis (2020)
Journal Article
Aithal, G. P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J. M., Wilkes, E. A., Moore, K., Leithead, J. A., Hayes, P. C., O'Brien, A. J., & Verma, S. (2020). Guidelines on the management of ascites in cirrhosis. Gut, 70(1), https://doi.org/10.1136/gutjnl-2020-321790

The British Society of Gastroenterology in collaboration with British Association for the Study of the Liver has prepared this document. The aim of this guideline is to review and summarise the evidence that guides clinical diagnosis and management o... Read More about Guidelines on the management of ascites in cirrhosis.

In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers (2020)
Journal Article
Atkinson, S. R., Grove, J. I., Liebig, S., Astbury, S., Vergis, N., Goldin, R., Quaglia, A., Bantel, H., Neil Guha, I., Thursz, M. R., Newcombe, P., Strnad, P., & Aithal, G. P. (2020). In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers. American Journal of Gastroenterology, 115(11), 1857-1868. https://doi.org/10.14309/ajg.0000000000000912

INTRODUCTION:

Up to 40% of patients with severe alcoholic hepatitis (AH) die within 6 months of presentation, making prompt diagnosis and appropriate treatment essential. We determined the associations between serum keratin-18 (K18) and histologi... Read More about In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers.

Comparison of the reverse bevel versus Franseen type endoscopic ultrasound needle (2020)
Journal Article
Wing Chow, C., Asma Haider, S., Ragunath, K., Aithal, G. P., James, M. W., Ortiz-Fernandez-Sordo, J., Dominic Aravinthan, A., & Vasan Venkatachalapathy, S. (2020). Comparison of the reverse bevel versus Franseen type endoscopic ultrasound needle. World Journal of Gastrointestinal Endoscopy, 12(9), 266-275. https://doi.org/10.4253/wjge.v12.i9.266

BACKGROUND
Reverse bevel (RB) needle is widely used for endoscopic ultrasound fine needle biopsy (EUS-FNB). A 3-plane symmetrical needle with Franseen geometry (FG) has recently become available.
AIM
To compare the clinical efficacy of FG to that... Read More about Comparison of the reverse bevel versus Franseen type endoscopic ultrasound needle.

Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: A large case-control study (2020)
Journal Article
Yan, H., Valdes, A. M., Vijay, A., Wang, S., Liang, L., Yang, S., Wang, H., Tan, X., Du, J., Jin, S., Huang, K., Jiang, F., Zhang, S., Zheng, N., Hu, Y., Cai, T., & Aithal, G. P. (2020). Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: A large case-control study. Clinical Pharmacology and Therapeutics, 108(6), 1185-1194. https://doi.org/10.1002/cpt.2047

The study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of COVID-19 in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zheijang, Chin... Read More about Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: A large case-control study.

Polygenic architecture informs potential vulnerability to drug-induced liver injury (2020)
Journal Article
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., Anayama, H., Dragan, Y., Shinozawa, T., & Takebe, T. (2020). Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nature Medicine, 26, 1541–1548. https://doi.org/10.1038/s41591-020-1023-0

Drug-Induced-Liver-Injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market, and this is partially due to the inability to identify patients who are at risk1. Here, we developed a polygenic ris... Read More about Polygenic architecture informs potential vulnerability to drug-induced liver injury.

Obesity, diabetes, coffee, tea and cannabis use alter risk for alcohol-related cirrhosis in two large cohorts of high-risk drinkers (2020)
Journal Article
Whitfield, J. B., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., Gleeson, D., Thompson, A., Stickel, F., Soyka, M., Daly, A. K., Cordell, H. J., Foroud, T., Lumeng, L., Pirmohamed, M., Nalpas, B., Jacquet, J.-M., Moirand, R., Nahon, P., Naveau, S., …Seth, D. (2021). Obesity, diabetes, coffee, tea and cannabis use alter risk for alcohol-related cirrhosis in two large cohorts of high-risk drinkers. American Journal of Gastroenterology, 116(1), 106-115. https://doi.org/10.14309/ajg.0000000000000833

Background:
Sustained high alcohol intake is necessary but not sufficient to produce alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, would assist in discovery of mechanisms and prediction of risk.... Read More about Obesity, diabetes, coffee, tea and cannabis use alter risk for alcohol-related cirrhosis in two large cohorts of high-risk drinkers.

Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors (2020)
Journal Article
Schwantes-An, T.-H., Darlay, R., Mathurin, P., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., Gleeson, D., Thompson, A., Muellhaupt, B., Stickel, F., Soyka, M., Goldman, D., Liang, T., Lumeng, L., Pirmohamed, M., Nalpas, B., Jacquet, J.-M., Moirand, R., …Seth, D. (2021). Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors. Hepatology, 73(5), 1920-1931. https://doi.org/10.1002/HEP.31535

Only a minority of heavy drinkers progress to alcohol‐related cirrhosis (ALC). The aim of this study was to identify common genetic variants that underlie risk for ALC. We analyzed data from 1,128 subjects of European ancestry with ALC and 614 heavy... Read More about Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study (2020)
Journal Article
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., Loomba, R., Abdelmalek, M. F., & Tacke, F. (2020). Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, 72(3), 892-905. https://doi.org/10.1002/hep.31108

Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers (2020)
Journal Article
Stickel, F., Lutz, P., Buch, S., Nischalke, H. D., Silva, I., Rausch, V., Fischer, J., Weiss, K. H., Gotthardt, D., Rosendahl, J., Marot, A., Elamly, M., Krawczyk, M., Casper, M., Lammert, F., Buckley, T. W., McQuillin, A., Spengler, U., Eyer, F., Vogel, A., …Morgan, M. Y. (2020). Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. Hepatology, 72(1), 88-102. https://doi.org/10.1002/hep.30996

Background & Aims:
Carriage of rs738409:G in patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with an increased risk for developing alcohol-related cirrhosis and hepatocellular carcinoma (HCC). Recently, rs72613567:TA in hydrox... Read More about Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.

Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome (2020)
Journal Article
Moolla, A., de Boer, J., Pavlov, D., Amin, A., Taylor, A., Gilligan, L., Hughes, B., Ryan, J., Barnes, E., Hassan-Smith, Z., Grove, J., Aithal, G. P., Verrijken, A., Francque, S., Van Gaal, L., Armstrong, M. J., Newsome, P. N., Cobbold, J. F., Arlt, W., Biehl, M., & Tomlinson, J. W. (2020). Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology and Therapeutics, 51(11), 1188-1197. https://doi.org/10.1111/apt.15710

Background: The development of accurate, non-invasive markers to diagnose and stage non-alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an invasive liver biopsy and to identify patients who are at the highest risk of hepatic... Read More about Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort (2020)
Journal Article
Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., Aithal, G. P., Allison, M., Yki-Järvinen, H., Vacca, M., Dufour, J.-F., Invernizzi, P., Prati, D., Ekstedt, M., Kechagias, S., Francque, S., …Daly, A. K. (2020). Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. Journal of Hepatology, 73(3), 505-515. https://doi.org/10.1016/j.jhep.2020.04.003

Background and Aims

Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most GWAS studies have adopted radiologically assessed hepatic triglyceride content as reference phenotype and s... Read More about Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

HLA-B*14:01 and HLA-B*35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury (2020)
Journal Article
Li, Y.-J., Phillips, E., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., Daly, A. K., Aithal, G. P., Barnhart, H., Chalasani, N., & Drug‐induced Liver Injury Network (DILIN). (2021). HLA-B*14:01 and HLA-B*35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury. Hepatology, 73(1), 268-281. https://doi.org/10.1002/hep.31258

Background and Aim
Trimethoprim‐sulfamethoxazole (TMP‐SMX) is an important cause of idiosyncratic drug induced liver injury (DILI), but its genetic risk factors are not well understood. We investigated the relationship between variants in the HLA C... Read More about HLA-B*14:01 and HLA-B*35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury.

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study (2020)
Journal Article
Newsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., Herring, R., Mantry, P., Kayali, Z., Hassanein, T., Lee, H.-M., & Aithal, G. P. (2020). Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. Journal of Hepatology, 73(2), 231-240. https://doi.org/10.1016/j.jhep.2020.03.024

Background & Aims:
Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production.
Method... Read More about Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.